NASER KALANI YAZD: Open Payments
NPI 1326064726 · DENVER, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,697 in 131 payments from 21 companies in 2025. Trend: 2023 $3,111 · 2024 $2,549 · 2025 $3,697
Food & beverage: $3,630Education: $66
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $455 |
| ABBVIE INC. | 17 | $447 |
| Teva Pharmaceuticals USA, Inc. | 9 | $385 |
| Bayer Healthcare Pharmaceuticals Inc. | 12 | $317 |
| Alkermes, Inc. | 10 | $284 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 10 | $261 |
| Neurocrine BioSciences, Inc. | 7 | $254 |
| Aimmune Therapeutics, Inc. | 9 | $240 |
| Sumitomo Pharma America, Inc. | 12 | $212 |
| Otsuka America Pharmaceutical, Inc. | 5 | $192 |
Products named: Kerendia, INGREZZA, ZENPEP, XIFAXAN, GEMTESA, AIRSUPRA, REXULTI, BREZTRI.
Industry payments across CO — which companies pay providers there.
